Clinical medicine

ProfNet Expert Alerts for May 14, 2021

Friday, May 14, 2021 - 9:00pm

I help families make sure their home air is clean and free of pollutants and pathogens.

Key Points: 
  • I help families make sure their home air is clean and free of pollutants and pathogens.
  • "\nCaroline can share advice on how to keep homes healthy and virus free - especially during high allergy seasons and under the cloak of the pandemic.
  • Caroline has developed many unique testing methods and products for residential consumers to evaluate their homes and maintain healthy environments economically.
  • She spends substantial time investigating new testing methods and products that will aid her clients with healthier living.

Sciton U.K. Announces Central London Flagship Showroom and Training Centre in Partnership with Skin Group International Ltd (SGI)

Friday, May 14, 2021 - 7:08pm

"Harley Street in London represents an area well known for excellence in medical aesthetics.

Key Points: 
  • "Harley Street in London represents an area well known for excellence in medical aesthetics.
  • Sciton offers aesthetic and medical devices for women\'s health, fractional and full-coverage skin resurfacing and skin revitalization, phototherapy, vascular and pigmentation lesions, scar reduction, acne, body contouring, and hair reduction.
  • Sciton operates on a worldwide basis with direct sales teams in the United States, Canada, Australia, United Kingdom, Ireland, Japan and distributor partners in more than 45 countries.
  • For more information, and a complete listing of Sciton systems, visit www.sciton.com .\n'

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

Friday, May 14, 2021 - 5:45pm

(Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.

Key Points: 
  • (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta\xc2\xae Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis.
  • The test uses targeted DNA and whole-transcriptome RNA sequencing to detect alterations in more than 50 genes known to be present in lung cancer.
  • The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.
  • Examples of forward-looking statements include, among others, statements regarding the ability of the Percepta Genomic Atlas to accurately detect known lung-cancer gene variants and help to guide treatment with targeted therapies.

Global Ankylosing Spondylitis Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Friday, May 14, 2021 - 3:17pm

b'The "Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study.

Key Points: 
  • b'The "Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nAnkylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual\'s spine, starting from lower back sacral bones.
  • Ankylosing spondylitis is started from an individual\'s sacroiliac joints, where the spinal cord connects with the pelvic girdle.
  • According to the recent population estimates the prevalence rate of ankylosing spondylitis in the U.S. is around 0.2-0.5 percent and based on market data from multiple countries the global incidence rate stood at 0.4-14 per 100,000 individuals.\n'

This Burned Out Millennial Corporate Executive Turned Her Self-Care Practices Into A Booming Business

Friday, May 14, 2021 - 3:00pm

Being diagnosed with Lupus taught me that many diseases, especially ones that are auto-immune, are often triggered by chronic stress.

Key Points: 
  • Being diagnosed with Lupus taught me that many diseases, especially ones that are auto-immune, are often triggered by chronic stress.
  • "\nYoung has spent the past five years managing her health primarily through mindfulness and holistic methods.
  • The Spa-Grade sized baths in particular come in a huge, beautiful bottle and are the largest luxury bath formulas on the market.
  • "\n"Throughout history, people have used and bathed with crystals to manifest blessings and for mental, physical and spiritual healing.

2021 Global Overactive Bladder Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Friday, May 14, 2021 - 2:29pm

b'The "Global Overactive Bladder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Overactive Bladder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Overactive Bladder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Overactive Bladder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Overactive Bladder patients, history of the disease at the population level (Overactive Bladder prevalence, Overactive Bladder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Overactive Bladder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Overactive Bladder market sizing, assessing market potential, and developing drug forecast models\nIdentify Overactive Bladder patients segments through age groups, gender, and disease sub-types\nEvaluate Overactive Bladder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005332/en/\n'

Global Urinary Incontinence Market Report to 2035 - Identify Patient Segments - ResearchAndMarkets.com

Friday, May 14, 2021 - 2:21pm

b'The "Global Urinary Incontinence Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Urinary Incontinence epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Urinary Incontinence Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Urinary Incontinence epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Urinary Incontinence patients, history of the disease at the population level (Urinary Incontinence prevalence, Urinary Incontinence incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand the targeted population for research and development, commercialization.\nDemographics: Urinary Incontinence patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Urinary Incontinence market sizing, assessing market potential, and developing drug forecast models\nIdentify Urinary Incontinence patients segments through age groups, gender, and disease sub-types\nEvaluate Urinary Incontinence market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005327/en/\n'

New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients

Friday, May 14, 2021 - 2:00pm

Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.

Key Points: 
  • Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.
  • However, more than half of cardiologists surveyed (53%) feel that their symptomatic severe AS patients are not as informed as they should be about their treatment options.\nThe findings indicate physicians recognize the importance of shared decision making to achieve individualized care for heart valve disease patients.
  • More than 3,400 responses were received from heart valve patients and caregivers.
  • Of the respondents, 94% identified as heart valve patients, 53% identified as aortic stenosis patients.\n'

Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Friday, May 14, 2021 - 1:15pm

\xe2\x80\x9cWe have made great strides to advance our pipeline programs in 2021 with the first patients dosed in both the Phase 2 TENACITY trial in triple negative breast cancer and the Phase 1 combination trial with Novartis in multiple myeloma.

Key Points: 
  • \xe2\x80\x9cWe have made great strides to advance our pipeline programs in 2021 with the first patients dosed in both the Phase 2 TENACITY trial in triple negative breast cancer and the Phase 1 combination trial with Novartis in multiple myeloma.
  • Ayala expects to initiate the pivotal RINGSIDE clinical trial of AL102 in adult and adolescent patients with desmoid tumors in the first half of 2021.
  • Ayala\xe2\x80\x99s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
  • For more information, visit www.ayalapharma.com .\n'

Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting

Friday, May 14, 2021 - 1:30pm

The primary endpoint is expected to be the reduction in oral glucose replacement with cornstarch while maintaining or improving glucose control assessed by continuous glucose monitoring.

Key Points: 
  • The primary endpoint is expected to be the reduction in oral glucose replacement with cornstarch while maintaining or improving glucose control assessed by continuous glucose monitoring.
  • These cell line engineering improvements result in a 2- to 5-fold yield improvement over the HeLa 2.0 platform, and a 50-fold yield improvement over HeLa 1.0.
  • It is caused by a defective gene coding for the enzyme G6Pase-\xce\xb1, resulting in the inability to regulate blood sugar (glucose).
  • It has been shown in preclinical studies to normalize levels of urinary orotic acid, a marker of ammonia metabolism.